Loading patent…
OwnerChristopher J. Wraight, George A. Werther +2inventors
InventorsChristopher J. Wraight, George A. Werther, Nicholas M. Dean, Kenneth J. Dobie
Estimating the term…
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding IGF-IR (SEQ ID NO:41) or a 5′ untranslated region thereof (SEQ ID NO:42), wherein said compound specifically hybridizes with said nucleic acid molecule and inhibits the expression of IGF-IR.
A method of screening for a modulator of IGF-IR gene expression, the method comprising the steps of:
A diagnostic method for identifying a disease state comprising identifying the presence of IGF-IR in a sample using a compound comprising at least an 8 nucleobase portion of sequence similarity with at least one of SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:30 and SEQ ID NO:36.
A method of ameliorating the effects of psoriasis, said method comprising contacting proliferating skin or skin capable of proliferation with an effective amount of one or more phosphorothioate nucleic acid molecules or chemical analogs thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation wherein the nucleic acid molecules are selected from SEQ ID NO:4 through 40.
A composition comprising a phosphorothioate nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or other medical disorder, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.
A synthetic or isolated ASO defined by SEQ ID NO:27.
A synthetic or isolated ASO defined by SEQ ID NO:30.
A synthetic isolated ASO defined by SEQ ID NO:36.
Use of a phosphorothioate ASO directed to the gene encoding IGF-IR in the manufacture of a medicament in the treatment of proliferation and/or inflammation of keratinocyte cells.
Dependencies are inferred from the claim text.